Parents want to do the best for their children, especially when they’re not feeling well. That often means giving liquid, over-the-counter (OTC) medications when they have a cold, fever or the flu. But even the best intentions can go wrong when it comes to dosing children’s OTC medicines.
OTC cough and cold medicines are safe and effective when used as directed – this includes always giving your child the precise, recommended dose. When it’s late at night and your child is sick, it may seem easier to reach for whatever is nearby, like a kitchen spoon, instead of taking the time to find the right dosing cup or syringe that came with the medicine. While 63 percent of parents surveyed say they prefer milliliter dosing devices to measure their children’s liquid medicine, 8 out of 10 parents* have given the wrong dose of liquid medicine to their child by accident.
To view the multimedia release go to:
https://www.multivu.com/players/English/8171651-chpa-educational-foundation-know-your-otcs/
DOWNLOAD: https://soundcloud.com/dmvlife/shab-maze-grindin Shab
Maze Debuts His First Visual "Grindin" Off His Anticipated Debut
Mixtape Titled "Bottle Service" Which is set to drop late spring!For more info and updates follow on instagram ShabMaze Twitter RealShabMaze http://www.youtube.com/watch?v=pnaCF4SJwk8
Since Newton witnessed a bubble rising from his bathtub, mankind has sought the stars. When William III of England commissioned Capt. William Kidd to command the first expedition to Mars in the late 1600s, he proved that space travel was both possible and profitable. Find out more at http://us.macmillan.com/arabellaofmars/daviddlevine-1 Arabella of Mars by David E Levine. Fantasy
At an event typically dominated by introductions from American auto companies, Kia Motors America (KMA) today stole the spotlight with the world debut of the all-new 2018 Kia Stinger (hereafter Stinger) at the North American International Auto Show. A five-passenger fastback sports sedan poised to redefine a segment currently populated by European automakers, the Stinger promises to be the highest-performance production vehicle in the company’s history and is backed by Kia Motors’ industry-leading quality and reliability. Offered with multiple engine and drivetrain configurations and luxurious accommodations, the Stinger is planned to go on sale in the U.S. late this year. Pricing will be announced closer to the vehicle’s launch date.
“Unlike any Kia that has come before it, the Stinger really is a dream car for us, and here today in Detroit, that dream is now a reality after years of commitment and hard work from a passionate group of designers, engineers and executives around the world,” said Orth Hedrick, vice president, product planning, Kia Motors America. “From its GT concept-car origins to the years of tuning and refining on the legendary Nurburgring circuit, no detail was too small to be obsessed over, and the result is simply stunning.”
To view the multimedia release go to:
http://www.multivu.com/players/English/8016951-kia-stinger-naias-2017/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
Drivers of late-model pickup trucks are likely to find themselves squinting into the darkness or temporarily blinding other drivers, the Insurance Institute for Highway Safety's latest headlight ratings show.
All four small pickups evaluated are available only with headlights that earn a poor rating. The same goes for 3 out of 7 large pickups. Only one large pickup, the Honda Ridgeline, is available with good-rated headlights, though all but the most expensive trim levels come with poor ones.
Pickups are the third vehicle category to be put through the IIHS headlight evaluations. Midsize cars were the first in March, followed by small SUVs in July.
IIHS launched its headlight ratings after finding that government standards based on laboratory tests allow for huge variation in the amount of illumination headlights provide in on-road driving. In the Institute's evaluations, engineers measure how far light is projected from a vehicle's low beams and high beams as the vehicle travels straight and on curves. Glare from low beams for oncoming drivers also is measured.
At an event typically dominated by introductions from American auto companies, Kia Motors America (KMA) today stole the spotlight with the world debut of the all-new 2018 Kia Stinger (hereafter Stinger) at the North American International Auto Show. A five-passenger fastback sports sedan poised to redefine a segment currently populated by European automakers, the Stinger promises to be the highest-performance production vehicle in the company’s history and is backed by Kia Motors’ industry-leading quality and reliability. Offered with multiple engine and drivetrain configurations and luxurious accommodations, the Stinger is planned to go on sale in the U.S. late this year. Pricing will be announced closer to the vehicle’s launch date.
“Unlike any Kia that has come before it, the Stinger really is a dream car for us, and here today in Detroit, that dream is now a reality after years of commitment and hard work from a passionate group of designers, engineers and executives around the world,” said Orth Hedrick, vice president, product planning, Kia Motors America. “From its GT concept-car origins to the years of tuning and refining on the legendary Nurburgring circuit, no detail was too small to be obsessed over, and the result is simply stunning.”
To view the multimedia release go to:
http://www.multivu.com/players/English/8016951-kia-stinger-naias-2017/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
